Corrigendum to “Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy” [Lung Cancer 69S1 (2010) S11–S18] (Lung Cancer (2010) 69 (S11–S17), (S0169500210701331), (10.1016/S0169-5002(10)70133-1));Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy

Lung Cancer

Volumn 69, Issue SUPPL. 1, 2010, Pages S32-

  Giuliani, Giovanni ^a   Grossi, Francesco ^b   de Marinis, Filippo ^c   Walzer, Stefan ^d  

^a Roche   (Italy)

^b SC Oncologia Medica A   (Italy)

^c Hospitals Lung Diseases Dept   (Italy)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bevacizumab; Cost effectiveness analysis; Markov model; Non small cell lung cancer (NSCLC); Pemetrexed

Indexed keywords

BEVACIZUMAB; CISPLATIN; GEMCITABINE; PEMETREXED;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; COST BENEFIT ANALYSIS; DRUG EFFICACY; HUMAN; ITALY; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 77956027875     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/S0169-5002(10)70137-9     Document Type: Erratum

References (34)

1. Wilking N, Högberg D, Jönsson B. Benchmarking report of lung cancer care in selected European Countries. 1-94. Karolinska Institutet, i3 Innovus, Stockholm School of Economics, 2008.
2. Toloza EM, Harpole L, McCrory DC Noninvasive staging of non- small cell lung cancer: a review of the current evidence. Chest 2003, 123(Suppl 1):137S-146S.
3. Wilking N, Jönsson B. A pan-European comparison regarding patient access to cancer drugs. Karolinska Institutet in collaboration with Stockholm School of Economics, Stockholm, Sweden, 2005 Sept 7.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346(2):92-98.
5. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non- small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
6. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non- small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27(8):1227-1234.
7. Ferrara N Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol 2002, 29:10-14.
8. EMEA. Press Release (pemetrexed). Meeting highlights from the Committee for Medicinal Products for Human Use, 26 29 May 2009. EMEA/CHMP/330580/2009.
9. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
10. Chouaid C, Atsou K, Hejblum G, Vergnenegre A Economics of treatments for non-small cell lung cancer. PharmacoEconomics 2009, 27(2):113-125.
11. Carlson JJ, Veenstra DL, Ramsey SD Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs 2008, 68(8):1105-1113.
12. Reif MS, Rivera P Evidence-based outcomes for patients with advanced non-small cell lung cancer. Semin Respir Crit Care Med 2000, 21(5):443-449.
13. Bordeleau L Pharmacoeconomics of systemic therapies for lung cancer. Treat Respir Med 2006, 5(2):129-141.
14. Ardizzoni A, Boni L, Tiseo M, Fossella F, Schiller JH, Paesmans M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
15. NICE. NICE Technology Appraisal Guidance 124: Pemetrexed for the treatment of non-small-cell lung cancer. 2007.
16. NICE. NICE Technology Appraisal 87. Erlotinib for the treatment of non-small-cell-lung cancer. 2008.
17. Alexander RJ, Herbst RS Expert insight into: new guidelines in the treatment of non-small-cell lung cancer (NSCLC). The Advanced Certificate Program: Lung Cancer Management last accessed 07.05.2009. http://www.projectsinknowledge.com/cp/Activity/index.cfm?jn=1868&sj=1871.01.
18. NICE. Updated Guide to the Methods of Technology Appraisal June 2008. ISBN: 1 84629 741 9.
19. Walzer S, de Castro Carpeño J, Vergnenègre A, Chouaid C, Heigener D, Bischoff HG, et al. An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-squamous non-small cell cancer (NSCLC). EJC Suppl 2009, 7(2):554.
20. Bucher HC, Guyatt GH, Griffith LE, Walter SD The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50(6):683-691.
21. CADTH. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. 2009.
22. Song F, Altman DG, Glenny AM, Deeks JJ Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326(7387):472.
23. Government Actuary's Department (GAD) Interim Life Tables (United Kingdom) http://www.gad.gov.uk/Life_Tables/Interim_Life_Tables.htm.
24. Nuijten M, Walzer S The costs of treating patients with advanced or recurrent non-small cell lung cancer (NSCLC) with bevacizumab plus cisplatin and gemcitabine compared with pemetrexed plus cisplatin in induction and maintenance therapy in Germany and Italy. Value in Health 2009, 12(3):PCN30.
25. Klein R, Muehlenbein C, Liepa AM, Babineaux S, Wielage R, Schwartzberg L Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009, 4(11):1404-1414.
26. Deeks JJ Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 2002, 21:1575-1600.
27. Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. NICE HTA 2001, 5(32):1-195.
28. Hope T, Savulescu J, Hendrick J Medical ethics and law: the core curriculum 2003, Churchill Livingstone, Edinburgh.
29. Berthelot JM, Will P, Evans WK, Coyle D, Earle CC, Bordeleau L Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J Natl Cancer Inst 2000, 92(16):1321-1329.
30. Leighl N, Zatloukal P, Mezger J, Ramlau R, Archer V, Moore N, et al. Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL). J Clin Oncol 2009, 27(Suppl). abstract #8050.
31. Ng R, Mittmann N, Florescu M, Shepherd FA, Salvarrey A, Seymour T, et al. An economic analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) JBR.10, a randomized trial of adjuvant vinorelbine plus cisplatin versus observation in early stage non-small cell lung cancer (NSCLC). J Clin Oncol 2006, 24(18S):7155.
32. Smith TJ, Hillner BE, Neighbors DM, McSorley PA, Le Chevalier T Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995, 13:2166-2173.
33. Gridelli C, Ferrara C, Guerriero C, Palazzo S, Grasso G, Pavese I, et al. Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. J Thorac Oncol 2007, 2(6):475-480.
34. Ciuleanu TE, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(9699):1432-1440.